You may not personally benefit from the study, but knowledge will be gained from it that may benefit others. 
ALTERNATIVES 
There are no known standard or effective therapies available for patients with both positive HIV-1 antibody 
and certain lymphomas. There are multiple medical centers using experimental and approved antiviral agents 
for patients with HIV infection, and also cancer chemotherapy for persons with lymphomas, but these 
therapies are not currently used in conjunction with transplantation. There is a study at our center evaluating 
transplantation and AZT without adoptive immunotherapy for HIV seropositive patients with lymphoma. 
OTHER INFORMATION 
Your HIV antibody tests results will be held in strictest confidence and no identifying information of any kind 
will be released to any other person or agency without your specific written permission except as required by 
law or court order. Test results will become a part of the medical record, and the medical record is available 
to other medical staff. Confidentiality will be protected in the reporting of results. 
You are not allowed to participate in this protocol if you are pregnant or breastfeeding and you are required 
to use appropriate contraception or abstinence if you are of childbearing potential. 
This treatment is being undertaken for the above described fatal disease. In agreeing to participate in a 
research program you are choosing to receive therapy that is not yet available outside of research institutions. 
This therapy is based on laboratory studies and/or exchange of information with other research centers. 
Although we hope it will benefit your condition, there is no assurance that it will do so, and it is possible that 
you may have unfavorable complications which might also be fatal. A maximum of 15 patients will be 
enrolled in this study. 
Significant new findings that may affect your decision to participate will be disclosed. 
Your decision to participate in this study is voluntary and you may withdraw your consent at any time, for 
any reason, without notice and without prejudice. However, withdrawal from this study during conditioning, 
without the transplant, may be fatal. 
It is understood that all medical expenses relating to, or arising from, these procedures will be paid by you 
and/or your insurance company. Financial compensation is not available in the event of physical injury, 
adverse effects, or death resulting from this research project. Medical care will be authorized by the 
attending physician. You and/or your insurance company will be responsible for all costs arising from the 
medical care. Isolation, culture, and administration of lymphocytes for adoptive immunotherapy will be done 
at no cost to you or your insurance company. 
In order to evaluate the results of this study, your medical records will need to be available to other 
physicians and researchers associated with the research project. The Food and Drug Administration, 
Burroughs Wellcome Co., Immunex Corporation and the National Institutes of Health will also have access to 
this information. Precautions to maintain confidentiality will be taken. Your personal identity will not be 
revealed in any publication or results. Study records will be maintained indefinitely for the purpose of 
analysis and follow-up. 
If you have questions about the research please contact your attending physician. If you have any questions 
Recombinant DNA Research, Volume 15 
[ 639 ] 
